HUTCHMED (China) signs exclusive licensing deal with GSK for investigational cancer drug

HUTCHMED (China)

03/09/2026 05:22

Sept 3 (Reuters) - HUTCHMED (China) 0013.HK said on Thursday its unit had signed an exclusive development and licensing agreement with a subsidiary of GSK GSK.L to develop and commercialise its investigational cancer drug, HMPL-A830.
The agreement grants the British drug maker's unit worldwide rights to develop and commercialise the drug outside Mainland China, Hong Kong, Macau and Taiwan.

 (Reporting by Jasmeen Ara Shaikh in Bengaluru; Editing by Subhranshu Sahu)
 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))